News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
715,234 Results
Type
Article (40855)
Company Profile (287)
Press Release (674082)
Multimedia
Podcasts (77)
Webinars (17)
Section
Business (205434)
Career Advice (2030)
Deals (35596)
Drug Delivery (101)
Drug Development (81458)
Employer Resources (173)
FDA (16344)
Job Trends (14976)
News (347251)
Policy (32796)
Tag
Academia (2580)
Accelerated approval (15)
Adcomms (24)
Allergies (113)
Alliances (49934)
ALS (132)
Alzheimer's disease (1556)
Antibody-drug conjugate (ADC) (206)
Approvals (16430)
Artificial intelligence (383)
Autoimmune disease (63)
Automation (25)
Bankruptcy (364)
Best Places to Work (11662)
BIOSECURE Act (21)
Biosimilars (146)
Biotechnology (190)
Bladder cancer (126)
Brain cancer (44)
Breast cancer (473)
Cancer (3685)
Cardiovascular disease (293)
Career advice (1706)
Career pathing (33)
CAR-T (222)
CDC (43)
Cell therapy (599)
Cervical cancer (31)
Clinical research (68123)
Collaboration (1279)
Company closure (4)
Compensation (908)
Complete response letters (42)
COVID-19 (2689)
CRISPR (71)
C-suite (544)
Cystic fibrosis (127)
Data (4320)
Decentralized trials (2)
Denatured (27)
Depression (93)
Diabetes (414)
Diagnostics (6549)
Digital health (32)
Diversity (10)
Diversity, equity & inclusion (45)
Drug discovery (178)
Drug pricing (156)
Drug shortages (28)
Duchenne muscular dystrophy (190)
Earnings (88805)
Editorial (45)
Employer branding (21)
Employer resources (150)
Events (115671)
Executive appointments (925)
FDA (18693)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (6)
Frontotemporal dementia (13)
Funding (1163)
Gene editing (157)
Generative AI (28)
Gene therapy (471)
GLP-1 (863)
Government (4613)
Grass and pollen (5)
Guidances (337)
Healthcare (18879)
HIV (42)
Huntington's disease (35)
IgA nephropathy (57)
Immunology and inflammation (205)
Immuno-oncology (16)
Indications (52)
Infectious disease (2901)
Inflammatory bowel disease (173)
Inflation Reduction Act (14)
Influenza (88)
Intellectual property (179)
Interviews (314)
IPO (16641)
IRA (50)
Job creations (3674)
Job search strategy (1439)
Kidney cancer (14)
Labor market (69)
Layoffs (539)
Leadership (24)
Legal (7974)
Liver cancer (84)
Longevity (11)
Lung cancer (530)
Lymphoma (256)
Machine learning (28)
Management (59)
Manufacturing (567)
MASH (127)
Medical device (13610)
Medtech (13631)
Mergers & acquisitions (19812)
Metabolic disorders (1015)
Multiple sclerosis (130)
NASH (17)
Neurodegenerative disease (194)
Neuropsychiatric disorders (49)
Neuroscience (2490)
NextGen: Class of 2025 (6553)
Non-profit (4506)
Now hiring (56)
Obesity (477)
Opinion (240)
Ovarian cancer (130)
Pain (147)
Pancreatic cancer (166)
Parkinson's disease (224)
Partnered (27)
Patents (394)
Patient recruitment (297)
Peanut (52)
People (58519)
Pharmaceutical (67)
Pharmacy benefit managers (23)
Phase I (21223)
Phase II (29996)
Phase III (22333)
Pipeline (2632)
Policy (245)
Postmarket research (2565)
Preclinical (9038)
Press Release (66)
Prostate cancer (187)
Psychedelics (42)
Radiopharmaceuticals (256)
Rare diseases (586)
Real estate (5981)
Recruiting (68)
Regulatory (23469)
Reports (51)
Research institute (2355)
Resumes & cover letters (352)
Rett syndrome (15)
RNA editing (14)
RSV (61)
Schizophrenia (121)
Series A (194)
Series B (146)
Service/supplier (13)
Sickle cell disease (72)
Special edition (20)
Spinal muscular atrophy (149)
Sponsored (34)
Startups (3655)
State (2)
Stomach cancer (14)
Supply chain (92)
Tariffs (80)
The Weekly (48)
Vaccines (897)
Venture capital (64)
Weight loss (311)
Women's health (53)
Worklife (17)
Date
Today (163)
Last 7 days (600)
Last 30 days (2231)
Last 365 days (30702)
2025 (24114)
2024 (35339)
2023 (40185)
2022 (51297)
2021 (55844)
2020 (54163)
2019 (46660)
2018 (35133)
2017 (32235)
2016 (31639)
2015 (37725)
2014 (31462)
2013 (26506)
2012 (28774)
2011 (29430)
2010 (27529)
Location
Africa (730)
Alabama (71)
Alaska (7)
Arizona (265)
Arkansas (13)
Asia (38844)
Australia (6355)
California (9052)
Canada (2783)
China (826)
Colorado (381)
Connecticut (387)
Delaware (253)
Europe (83735)
Florida (1350)
Georgia (295)
Hawaii (2)
Idaho (61)
Illinois (707)
India (45)
Indiana (431)
Iowa (17)
Japan (310)
Kansas (118)
Kentucky (33)
Louisiana (16)
Maine (67)
Maryland (1190)
Massachusetts (6634)
Michigan (278)
Minnesota (526)
Mississippi (4)
Missouri (107)
Montana (29)
Nebraska (25)
Nevada (102)
New Hampshire (70)
New Jersey (2488)
New Mexico (28)
New York (2462)
North Carolina (1237)
North Dakota (8)
Northern California (4168)
Ohio (277)
Oklahoma (20)
Oregon (37)
Pennsylvania (1903)
Puerto Rico (18)
Rhode Island (43)
South America (1102)
South Carolina (47)
South Dakota (1)
Southern California (3487)
Tennessee (145)
Texas (1398)
United States (32892)
Utah (268)
Virginia (219)
Washington D.C. (77)
Washington State (761)
West Virginia (4)
Wisconsin (77)
Wyoming (1)
715,234 Results for "yield10 bioscience inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
Yield10 Bioscience Announces Delisting from Nasdaq
Yield10 Bioscience, Inc., an agricultural bioscience company, announced that Company has received a final delisting notice from Nasdaq.
May 15, 2024
·
3 min read
Business
Yield10 Bioscience Announces Fourth Quarter and Full Year 2023 Financial Results
Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10" or the “Company”), an agricultural bioscience company, today reported financial results for the fourth quarter and full year ended December 31, 2023.
April 1, 2024
·
14 min read
Genetown
Yield10 Bioscience Announces Addition of Camelina to INTERLINE® Herbicide Label
Yield10 Bioscience, Inc. today announced that UPL Ltd. (“UPL”) has received U.S. Environmental Protection Agency (“EPA”) approval to amend the label language of INTERLINE ® Herbicide to include the oilseed Camelina sativa (“Camelina”).
May 23, 2024
·
4 min read
Genetown
Yield10 Bioscience Announces 1-for-24 Reverse Stock Split
Yield10 Bioscience, Inc., an agricultural bioscience company, announced that it will effect a 1-for-24 reverse stock split of its common stock, following stockholder approval of the reverse stock split at its special stockholder meeting held on April 26, 2024.
May 1, 2024
·
5 min read
Business
Yield10 Bioscience Announces First Quarter 2024 Financial Results-Earns $1 million in milestone payments from Vision Bioenergy Oilseeds
Yield10 Bioscience, Inc., an agricultural bioscience company, reported financial results for the first quarter ended March 31, 2024.
May 15, 2024
·
12 min read
Genetown
Rothamsted Research Grants Yield10 Bioscience an Exclusive, Global Commercial License to Advanced Technology for Producing Omega-3 Products in Camelina
Yield10 Bioscience, Inc., an agricultural bioscience company, announced that U.K.-based Rothamsted Research Limited has granted to the Company an exclusive global, commercial license to advanced technology for producing sustainable omega-3 products in Camelina sativa.
June 17, 2024
·
7 min read
Genetown
USDA-APHIS Determines that Yield10 Bioscience’s Omega-3 Camelina Varieties May Be Planted and Bred in the United States
Yield10 Bioscience, Inc. announced that USDA-APHIS’s Biotechnology Regulatory Services has determined that Yield10’s Camelina sativa varieties developed using genetic engineering to produce omega-3 fatty acids are not subject to the regulations under 7 CFR part 340, and may be grown and bred in the United States.
March 21, 2024
·
6 min read
BioMidwest
Yield10 Bioscience Grants Global License to VISION Bioenergy Oilseeds for Herbicide Tolerant Camelina Cultivated for the Production of Biofuel Feedstock
Yield10 Bioscience, Inc. and VISION Bioenergy Oilseeds, LLC announced that Yield10 has granted to VISION a global license to certain proprietary varieties of Camelina sativa for the production of feedstock oil for biofuels.
February 14, 2024
·
7 min read
Business
Yield10 Bioscience Announces Third Quarter 2023 Financial Results
Yield10 Bioscience, Inc., an agricultural bioscience company, reported financial results for the three and nine months ended September 30, 2023.
November 14, 2023
·
13 min read
Genetown
USDA-APHIS Determines that Yield10 Bioscience’s Glufosinate Tolerant Camelina May Be Planted and Bred in the United States
Yield10 Bioscience, Inc., an agricultural bioscience company, announced that USDA-APHIS’s Biotechnology Regulatory Services has determined that Yield10’s glufosinate tolerant Camelina sativa may be grown and bred in the United States.
November 15, 2023
·
6 min read
1 of 71,524
Next
